Gene change in chronic lymphocytic leukemia and non-hodgkin's lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks for a specific gene change (Notch 1 mutation) in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). It may help doctors understand how these diseases behave and guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to sign a consent form.
- You must have a diagnosis of either chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL).
- You cannot be currently receiving chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a genetic change called SF3B1 mutation in people with acute or chronic lymphocytic leukemia. It aims to understand how this mutation affects the disease and may help guide treatment decisions.
This study is examining levels of a protein called LEF1 in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if LEF1 can help predict survival and confirm diagnosis.
This study follows people newly diagnosed with chronic lymphocytic leukemia (CLL), a type of blood cancer, to learn more about the disease and how it progresses. By participating, you help researchers understand CLL better, which may improve future treatments.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new Chronic Lymphocytic Leukemia (CLL)- Non-Hodgins's Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.